Here’s what you should know.
1. Valeant’s Salix Pharmaceuticals and its Bausch & Lomb segments accounted for 76 percent of Valeant’s business. Combined, both products grew organically by 10 percent.
2. Mr. Papa also noted Salix’s irritable bowel syndrome Xifaxan hit $1 billion in sales in the first quarter already.
3. He said drugs like Xifaxan will help Valeant pay down its $25 billion debt load.
4. Mr. Papa is betting on Valeant’s research and development department to drive shareholder value and help the company improve its earnings.
5. He also referenced the company’s decision to rename the company Bausch Health Companies.
https://www.beckersasc.com/supply-chain/valeant-no-more-valeant-pharmaceuticals-rebranding-as-bausch-health-companies.html
More articles on supply chain:
Hoag Orthopedic Institute hosts 1st mock surgery event — 5 highlights’
Envision to transition 95% of revenue in-network by the end of 2018
Envision blames ambulatory revenue drop on flu, sees Q2 recovery: 5 things to know from Q1
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.